Effect of Mannitol 20% Versus Hypertonic Saline 7.5% in Brain Metabolism and Oxygenation

NCT ID: NCT03573999

Last Updated: 2021-05-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 54 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-06-29
• Study Completion Date: 2019-12-20

Brief Summary

Usage of osmotic agents is a standard practice in neuroanesthesia since cerebral edema is a very common situation for patients with pathology in the brain. Cerebral edema is defined as the accumulation of fluid in the intracellular or extracellular compartments of the brain. Among other situations that have nothing to do with the brain, a supratentorial pathology such as a tumor, traumatic injury or an aneurysm, will lead to disruption of blood-brain barrier, and energy crisis of the cells that will cause mainly vasogenic and cytotoxic cerebral edema. The most common monitoring method for "measuring" cerebral edema is ICP (intracranial pressure) in which normal values are (with differences in the bibliography) 10-15 mmHg.

The osmotic agents used most in neuroanesthesia are mannitol 20% and hypertonic NaCl 7.5% or 3%. Their brain relaxation effectiveness is supposed to be quite the same between the two different agents. Their main difference is that mannitol induces diuresis. Also, electrolyte disorders are another possibility after mannitol infusion. On the other hand, NaCl 7.5% causes vasodilation, does not induce diuresis and hemodynamically, even though it reduces SBP, it raises CO because of its excessive vasodilation. But both reduce cerebral edema due to the change of osmotic pressure in the vessels, that leads to extracting water from brain cells.

A supratentorial craniotomy is de facto worsening the oxygenation and metabolism condition of the surgical site, adding to the problem the intracranial pathology causes in the first place. So if oxygen provided is low and the metabolic rate is high, the rate of anaerobic metabolism will raise. Measuring the oxygen in the jugular bulb is the most reliable monitoring method of cerebral oxygenation and metabolism.

It becomes evident that optimization of cerebral oxygenation during a craniotomy will possibly affect the outcome of a patient, by improving it. So, if any superiority of one osmotic agent over the other could be demonstrated this will be very helpful in the decision making in routine clinical practice.

Detailed Description

Each participant will receive standard monitoring (ECG, SpO2, SBP, BIS, urine output, temperature). More detailed hemodynamic monitoring will be obtained by Edwards Lifesciences ClearSight system (CO, CI, SV, SVI, SVV, SVR, SVRI).

TCI Propofol and Remifentanil will be the agents of choice for induction and maintenance in anesthesia and cisatracurium will be used for neuromuscular blockade for intubation.

Protective mechanical ventilation will be chosen (7ml/kg IBW) with a Respiratory rate to obtain a PaCO2 of 35-40 mmHg. PEEP will be changed for the best PaO2/FiO2 ratio and FiO2 of choice will be 0.5.

The radial artery catheterization will be applied for direct blood pressure measurement and arterial blood gas sampling ( pH, PaO2, PaCO2, HCO3, BE, Osmolality, Lactic acid, Hb, Glucose, Na, K will be measured).

The jugular bulb ipsilateral to the craniotomy site will be catheterized for receiving blood samples for blood gas analysis. The following oxygenation and metabolic parameters / derivates will be measured or calculated: SjvO2, pH, PjvO2, PjvCO2, HCO3, BE, Osmolality, Lactic acid jv, Hb, Glucose, Na, K, AjvDO2, AjvCO2, O2ERbr, eRQbr, AjvDL, and LOI.

The osmotic agent will be administered 20 minutes before dura matter incision. Before the dura mater opening the subdural space pressure will be measured and relevant CPP will be calculated. Brain Relaxation Score will be assessed by the neurosurgeon.

Phases

• T0: 5 minutes before administration of the osmotic agent
• T15: 15 minutes after administration of the osmotic agent
• T30: 30 minutes after administration of the osmotic agent
• T60: 60 minutes after administration of the osmotic agent
• T90: 90 minutes after administration of the osmotic agent
• T120: 120 minutes after administration of the osmotic agent
• T180: 180 minutes after administration of the osmotic agent
• T240: 240 minutes after administration of the osmotic agent Blood samples for measuring S-100b will be collected at phases T0, T240 and 12 hours after osmotic agent administration.

Postoperative complications, length of ICU stay, GOS-E (Glasgow Outcome Scale) and other neurological deficits will be recorded.

Conditions

Brain Edema; Metabolic Disturbance; Electrolyte and Fluid Balance Conditions

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Mannitol 20%

Mannitol 20% (4.6ml/kg) will be administered 20 minutes before dura matter opening.

Group Type: ACTIVE_COMPARATOR

Mannitol

Intervention Type: DRUG

4.6 ml/kg will be administered before dura opening

Hypertonic saline 7.5%

Hypertonic saline 7.5% (2ml/kg) will be administered 20 minutes before dura matter opening

Group Type: EXPERIMENTAL

NaCl 7.5%

Intervention Type: DRUG

2 ml/kg will be administered before dura opening

Interventions

Mannitol

4.6 ml/kg will be administered before dura opening

Intervention Type: DRUG

NaCl 7.5%

2 ml/kg will be administered before dura opening

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Adult patients aged between 18 and 75 years
• ASA Physical status 1 to 3
• Elective or semi-elective supratentorial craniotomy
• Signed informed consent

Exclusion Criteria

• Craniotomy for suprasellar pathologies
• Re-craniotomy at the same site
• Perioperative sodium disorders (Na <130 mEq/L or >150 mEq/L)
• Administration of intravenous mannitol or hypertonic saline 7.5% 24 hours or less before the surgery
• Preoperative obstructive hydrocephalus
• Congestive heart failure
• Renal failure

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Aristotle University Of Thessaloniki

OTHER

Sponsor Role: lead

Responsible Party

Georgia Tsaousi

Assistant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Georgia Tsaousi

Role: PRINCIPAL_INVESTIGATOR

Aristotle University Of Thessaloniki

Locations

AHEPA University Hospital

Thessaloniki, , Greece

Georgia Tsaousi

Thessaloniki, , Greece

Countries

Greece

Other Identifiers

OsmoMetOx

Identifier Type: -

Identifier Source: org_study_id